Keyword: Massachusetts Institute of Technology
Biosims haven't worked, experts say. Instead, it's time to for an independent body to set fair biologic prices after the drugs lose exclusivity.
Here’s a radical solution for hepatitis C treatment in the U.S.: The government could buy Gilead Sciences. Price: $156 billion. Payoff: Curing hep C patients at one-third the cost.